(Q37280737)

English

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

scientific article published on 22 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). (English)

1 reference

Europe PubMed Central

19 August 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

autotransplantation

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

7

object named as

Bart Barlogie

1 reference

Europe PubMed Central

19 August 2017

Andrzej Jakubowiak

5

object named as

Andrzej J Jakubowiak

1 reference

Europe PubMed Central

19 August 2017

4

object named as

Brian G M Durie

1 reference

Europe PubMed Central

19 August 2017

author name string

Mohamad A Hussein

1

1 reference

Europe PubMed Central

19 August 2017

Vanessa Bolejack

2

1 reference

Europe PubMed Central

19 August 2017

Jeffrey A Zonder

3

1 reference

Europe PubMed Central

19 August 2017

John J Crowley

6

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

22 June 2009

1 reference

Europe PubMed Central

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

19 August 2017

27

1 reference

Europe PubMed Central

19 August 2017

21

1 reference

Europe PubMed Central

19 August 2017

3510-3517

1 reference

Europe PubMed Central

19 August 2017

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Role of autologous stem-cell transplantation in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

6 September 2017

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

3 September 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

3 September 2018

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

3 September 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

3 September 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717757

3 September 2018

One or two autografts for myeloma?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19546405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19546405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19546405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.9240

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37280737&oldid=2139441283"